Therapeutic Landscapes in Colorectal Carcinoma
Author Contributions
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Wolf, A.; Fontham, E.T.; Church, T.R.; Flowers, C.R.; Guerra, C.E.; LaMonte, S.J.; Etzioni, R.; McKenna, M.T.; Oeffinger, K.C.; Tina Shih, Y.-C.; et al. Colorectal Cancer Screening for Average-Risk Adults: 2018 Guideline Update From the American Cancer Society; 6 Independent Retired Physician and Patient Advocate. CA A Cancer J. Clin. 2018, 68, 250–281. [Google Scholar] [CrossRef] [PubMed]
- Riihimäki, M.; Hemminki, A.; Sundquist, J.; Hemminki, K. Patterns of Metastasis in Colon and Rectal Cancer. Sci. Rep. 2016, 6, 29765. [Google Scholar] [CrossRef] [PubMed]
- Brenner, H.; Kloor, M.; Pox, C.P. Colorectal Cancer. Lancet 2014, 383, 1490–1502. [Google Scholar] [CrossRef] [PubMed]
- Van Cutsem, E.; Köhne, C.H.; Láng, I.; Folprecht, G.; Nowacki, M.P.; Cascinu, S.; Shchepotin, I.; Maurel, J.; Cunningham, D.; Tejpar, S.; et al. Cetuximab plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J. Clin. Oncol. 2011, 29, 2011–2019. [Google Scholar] [CrossRef] [PubMed]
- Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science 2017, 357, 409–413. [Google Scholar] [CrossRef] [PubMed]
- Jaafar, R.F.; Ibrahim, Z.; Ataya, K.; Hassanieh, J.; Ard, N.; Faraj, W. Receptor-Interacting Serine/Threonine-Protein Kinase-2 as a Potential Prognostic Factor in Colorectal Cancer. Medicina 2021, 57, 709. [Google Scholar] [CrossRef] [PubMed]
- Hause, R.J.; Pritchard, C.C.; Shendure, J.; Salipante, S.J. Classification and Characterization of Microsatellite Instability across 18 Cancer Types. Nat. Med. 2016, 22, 1342–1350. [Google Scholar] [CrossRef] [PubMed]
- Lungulescu, C.; Croitoru, V.M.; Volovat, S.R.; Cazacu, I.M.; Turcu-Stiolica, A.; Gheonea, D.I.; Sur, D.; Lungulescu, C.V. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population—A Bi-Institutional Pilot Study. Medicina 2021, 57, 847. [Google Scholar] [CrossRef] [PubMed]
- Ossami Saidy, R.R.; Wegener, E.; Uluk, D.; Dittrich, L.; Schöning, W.; Lurje, G.; Öllinger, R.; Modest, D.P.; Tacke, F.; Haase, O.; et al. A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation. Medicina 2022, 58, 1755. [Google Scholar] [CrossRef] [PubMed]
- Chen, P.-H.; Jhou, H.-J.; Chung, C.-H.; Wu, Y.-Y.; Huang, T.-C.; Lee, C.-H.; Chien, W.-C.; Chen, J.-H. Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer. Medicina 2022, 59, 10. [Google Scholar] [CrossRef] [PubMed]
- Yeh, J.H.; Tsai, H.L.; Chen, Y.C.; Li, C.C.; Huang, C.W.; Chang, T.K.; Su, W.C.; Chen, P.J.; Liu, Y.P.; Wang, J.Y. BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer&emdash;A Case Series Study Target Therapy of BRAF-Mutated MCRC. Medicina 2021, 57, 1339. [Google Scholar] [CrossRef] [PubMed]
- Voutsadakis, I.A. Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Medicina 2022, 58, 1498. [Google Scholar] [CrossRef] [PubMed]
- De Summa, S.; Danza, K.; Pilato, B.; Matera, G.; Fasano, R.; Calabrese, A.; Lacalamita, R.; Silvestris, N.; Tommasi, S.; Argentiero, A.; et al. A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. Medicina 2021, 57, 1241. [Google Scholar] [CrossRef] [PubMed]
- Voutsadakis, I.A. Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer. Medicina 2021, 57, 860. [Google Scholar] [CrossRef] [PubMed]
- Angius, A.; Scanu, A.M.; Arru, C.; Muroni, M.R.; Carru, C.; Porcu, A.; Cossu-Rocca, P.; De Miglio, M.R. A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer. Medicina 2021, 57, 1257. [Google Scholar] [CrossRef] [PubMed]
- Kopel, J.; Ristic, B.; Brower, G.L.; Goyal, H. Global Impact of COVID-19 on Colorectal Cancer Screening: Current Insights and Future Directions. Medicina 2022, 58, 100. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Scanu, A.M.; De Miglio, M.R. Therapeutic Landscapes in Colorectal Carcinoma. Medicina 2023, 59, 821. https://doi.org/10.3390/medicina59050821
Scanu AM, De Miglio MR. Therapeutic Landscapes in Colorectal Carcinoma. Medicina. 2023; 59(5):821. https://doi.org/10.3390/medicina59050821
Chicago/Turabian StyleScanu, Antonio Mario, and Maria Rosaria De Miglio. 2023. "Therapeutic Landscapes in Colorectal Carcinoma" Medicina 59, no. 5: 821. https://doi.org/10.3390/medicina59050821